83 related articles for article (PubMed ID: 8155738)
1. Studies on the urinary excretion of thromboxane B2 in Zellweger patients and control subjects: evidence for a major role for peroxisomes in the beta-oxidative chain-shortening of thromboxane B2.
de Waart DR; Koomen GC; Wanders RJ
Biochim Biophys Acta; 1994 Apr; 1226(1):44-8. PubMed ID: 8155738
[TBL] [Abstract][Full Text] [Related]
2. Peroxisomal chain-shortening of thromboxane B2: evidence for impaired degradation of thromboxane B2 in Zellweger syndrome.
Diczfalusy U; Vesterqvist O; Kase BF; Lund E; Alexson SE
J Lipid Res; 1993 Jul; 34(7):1107-13. PubMed ID: 8371058
[TBL] [Abstract][Full Text] [Related]
3. Urinary excretion of 2,3-dinor-thromboxane B1, a major metabolite of thromboxane B2 in the rat.
Chiabrando C; Corada M; Bachi A; Fanelli R
Prostaglandins; 1994 Jun; 47(6):409-22. PubMed ID: 7938613
[TBL] [Abstract][Full Text] [Related]
4. Increased urinary excretion of LTB4 and omega-carboxy-LTB4 in patients with Zellweger syndrome.
Mayatepek E; Flock B
Clin Chim Acta; 1999 Apr; 282(1-2):151-5. PubMed ID: 10340443
[TBL] [Abstract][Full Text] [Related]
5. Fractional conversion of thromboxane A2 and B2 to urinary 2,3-dinor-thromboxane B2 and 11-dehydrothromboxane B2 in the cynomolgus monkey.
Patrignani P; Morton H; Cirino M; Lord A; Charette L; Gillard J; Rokach J; Patrono C
Biochim Biophys Acta; 1989 Jul; 992(1):71-7. PubMed ID: 2752041
[TBL] [Abstract][Full Text] [Related]
6. Impaired degradation of prostaglandins and thromboxane in Zellweger syndrome.
Fauler J; Tsikas D; Mayatepek E; Keppler D; Frölich JC
Pediatr Res; 1994 Oct; 36(4):449-55. PubMed ID: 7816519
[TBL] [Abstract][Full Text] [Related]
7. Urinary excretion of thromboxane and prostacyclin metabolites during chronic low-dose aspirin: evidence for an extrarenal origin of urinary thromboxane B2 and 6-keto-prostaglandin F1 alpha in healthy subjects.
Chiabrando C; Rivoltella L; Martelli L; Valzacchi S; Fanelli R
Biochim Biophys Acta; 1992 Feb; 1133(3):247-54. PubMed ID: 1737057
[TBL] [Abstract][Full Text] [Related]
8. Increased thromboxane metabolites excretion in liver cirrhosis.
Davì G; Ferro D; Basili S; Iuliano L; Camastra C; Giammarresi C; Santarone S; Rocca B; Landolfi R; Ciabattoni G; Cordova C; Violi F
Thromb Haemost; 1998 Apr; 79(4):747-51. PubMed ID: 9569186
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of prostaglandin F2 alpha in Zellweger syndrome. Peroxisomal beta-oxidation is a major importance for in vivo degradation of prostaglandins in humans.
Diczfalusy U; Kase BF; Alexson SE; Björkhem I
J Clin Invest; 1991 Sep; 88(3):978-84. PubMed ID: 1885782
[TBL] [Abstract][Full Text] [Related]
10. Structure and quantitative determination of the major urinary metabolite of thromboxane B2 in the guinea pig.
Svensson J
Prostaglandins; 1979 Mar; 17(3):351-65. PubMed ID: 472333
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of thromboxane B2 in man. Identification of the major urinary metabolite.
Roberts LJ; Sweetman BJ; Payne NA; Oates JA
J Biol Chem; 1977 Nov; 252(21):7415-7. PubMed ID: 914816
[TBL] [Abstract][Full Text] [Related]
12. Formation of prostacyclin and thromboxane in man as measured by the main urinary metabolites.
Fischer S; Bernutz C; Meier H; Weber PC
Biochim Biophys Acta; 1986 Apr; 876(2):194-9. PubMed ID: 3754157
[TBL] [Abstract][Full Text] [Related]
13. Urinary excretion of dicarboxylic acids from patients with the Zellweger syndrome. Importance of peroxisomes in beta-oxidation of dicarboxylic acids.
Björkhem I; Blomstrand S; Hågå P; Kase BF; Palonek E; Pedersen JI; Strandvik B; Wikström SA
Biochim Biophys Acta; 1984 Aug; 795(1):15-9. PubMed ID: 6466694
[TBL] [Abstract][Full Text] [Related]
14. Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man.
Ciabattoni G; Pugliese F; Davi G; Pierucci A; Simonetti BM; Patrono C
Biochim Biophys Acta; 1989 Jul; 992(1):66-70. PubMed ID: 2752040
[TBL] [Abstract][Full Text] [Related]
15. Prostacyclin and thromboxane in pregnant and nonpregnant women in response to exercise.
Rauramo I; Ilmonen S; Viinikka L; Ylikorkala O
Obstet Gynecol; 1995 Jun; 85(6):1027-30. PubMed ID: 7770249
[TBL] [Abstract][Full Text] [Related]
16. Urinary thromboxane B2 and 2,3-dinor-thromboxane B2 in the neonate born at full-term age.
Van Geet C; Arnout J; Eggermont E; Vermylen J
Eicosanoids; 1990; 3(1):39-43. PubMed ID: 2328133
[TBL] [Abstract][Full Text] [Related]
17. Measurement of urinary 2,3-dinor-thromboxane B2 and thromboxane B2 using bonded-phase phenylboronic acid columns and capillary gas chromatography--negative-ion chemical ionization mass spectrometry.
Lawson JA; Brash AR; Doran J; FitzGerald GA
Anal Biochem; 1985 Nov; 150(2):463-70. PubMed ID: 4091270
[TBL] [Abstract][Full Text] [Related]
18. Increased thromboxane formation in diabetic pregnancy as a possible contributor to preeclampsia.
Van Assche FA; Spitz B; Hanssens M; Van Geet C; Arnout J; Vermylen J
Am J Obstet Gynecol; 1993 Jan; 168(1 Pt 1):84-7. PubMed ID: 8420355
[TBL] [Abstract][Full Text] [Related]
19. Metabolism of thromboxane B2 in the monkey.
Roberts LJ; Sweetman BJ; Oates JA
J Biol Chem; 1978 Aug; 253(15):5305-18. PubMed ID: 97291
[TBL] [Abstract][Full Text] [Related]
20. Preparation of 2,3,4,5-tetranor-thromboxane B2, the major urinary catabolite of thromboxane B2 in the rat.
Pace-Asciak CR; Edwards NS
Methods Enzymol; 1982; 86():604-7. PubMed ID: 7132772
[No Abstract] [Full Text] [Related]
[Next] [New Search]
